Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Poster Exhibitions

Tuesday lulv 9. - - - - - I IF - - ool

TuPeB4579 Improving in-vitro measures of antiviral
pharmacodynamic action: proof of concept and
implications
N M Ferguson', C Fraser', A Hsu2,
G R Granneman2, A Molla2, D Kempf, E Sun2,
R M Anderson' (United Kingdom; 2United States)
TuPeB458o Preliminary results of intensification therapy with
amprenavir (APV)/ ritonavir (RTV) in two
differents doses: 1200 (APV)/ 200 (RTV) qd vs
6oo (APV)/ loo (RTV) bid in a heavily pretreated
patients failing HAART
J L Blanco, M Sarasa, M Arnedo, A Milinkovic,
Y Lopez-Pua, E Martinez, j Murillas, M Garcia,
T Pumarola, X Came, J M Gatell, J Mallolas (Spain)
TuPeB4581 Intensification therapy with lopinavir/ ritonavir in
heavily pretreated patients with virological failure
J Blanco, J Mallolas, M Arnedo, M Sarasa,
Y Lopez-Pua, A Milinkovic, E Martinez, M Garcia,
M Lonca, T Pumarola, T Came, J M Gatell (Spain)
TuPeB4582 HIV Genotyping and drug levels predict the
response to a RTV-SQV salvage therapy
L Valer, D Gonzalez de Requena, C de Mendoza,
P Labarga, A Garcia Henarejos, F Guerrero,
A Vergara, VSoriano (Spain)
TuPeB4583 Emergence of resistance mutations in children
treated with ddl plus d4T after treatment to
prevent mother-to-child transmission
C Pillay, G Gray, G Stevens, B ]ivkov, A Violari,
W Stevens, I McIntyre, L Morris (South Africa)

Tuesday

TuPeB4584

Prevelance of genotypic drug resistance in HIVinfected individuals in New York State:
the resistance study
M Parker, M Waters, B Agins, B Reilly, R Bennett,
A Aydemir, G Drusano, J Taylor (United States)

TuPeB4585 High incidence of primary NNRTI mutations and
M184V in isolates from therapy-experienced
adults entering the ZORRO Trial
JHernandez P Ruane, L You, S Hessenthaler,
ER Lanier (United States)
TuPeB4586 Isolated G19oA substituion of HIV reverse
transcriptase is associated with hypersensitivity
to Delaviridine (DLV)
E Uhlmann, P Tebas, GA Storch, W G Powderly,
Y Lie, M Bates, N S Hellman, M Q Arens
(United States)
TuPeB4587 Resistance profiles at baseline and following
virologic failure for subjects randomized to
receive Abacavir (ABC)/Efavirenz
(EFV)/Didanosine (ddl) + Hydroxyrea (HU) after
failing initial NRTI + PI therapy
ER Lanier, Q Liao, C Cohen, S Swindells,
D Berger, K Tashima, B Pobiner, S Griffith,
I Hernandez (United States)
TuPeB4588 First analysis of the Frankfurt HIV-1 resistance
database: distribution of mutational patterns
M Stuermer, Y Hermschulte, N Hanke,
S Staszewski, H W Doerr (Germany)
TuPeB4589 The use of strategic selective pressure for
salvage therapy
F Maggiolo, A Callegaro, D Ripamonti, M Rizzi,
CArici, GAntezana Camacho, A Goglio, F Suter
(Italy)
TuPeB459o Effect of the M184V mutation in HIV Reverse
Transcriptase (RT) on viral fitness in primary
infection
MA Wainberg, B Brenner, I P Routy, B Spira,
M Petrella, V Essebag, B Conway, R P Sekaly
(Canada)

TuPeB4591 Prevalence of antiretroviral drug-resistant HIV-i in
individuals with treatment failure in Argentina
AE Rubio G H Kijak, S E Pampuro, C Zala,
C Ochoa, P Cahn, H Salomon (Argentina)
TuPeB4592 Is L9oM mutation selected more frequently in
non-B subtype HIV1 infected patients failing on
Nelfinavir-containing HAART?
L Navaratne W Tong, I Christie, J Mullen,
S O'Shea, G DuMont, A DeRuiter, R Kulasegeram
(United Kingdom)
TuPeB4593 Case-control study of perinatal HIV-i transmission
and genotypic and phenotypic markers of reduced
susceptibility to zidovudine (ZDV)
L M Mofenson, I Lambert, ER Stiehm, R Kagan,
J Moye, D R Harris, J Bethel, W Meyer, M G Fowler,
B Mathieson, G Nemo, M Hering, N Hellmann
(United States)
TuPeB4594 Nelfinavir (NFV) resistance mutations during a
follow-up period of 108 weeks in PI-naive
patients treated with NFV-containing regimens in
an HIV clinic cohort
S Oka, K Tsuchiya, S Ida, A Yasuoka, Y Kikuchi,
N Tachikawa, K Teruya, S Kimura (Japan)
TuPeB4595 Limited Evolution of HIV resistance mutations in
patients maintained on a stable treatment
regimen despite low-level virological failure
MB Goetz FMoatamed, ZHan, WA O'Brien,
MA Ferguson (United States)
TuPeB4596 Genotypic resistance profiles and subtypes of
HIV-1 in Brazilian children failing HAART
D M Machado, S C Fernandes, W S Freire,
R S Diaz, CS Pannuti, A Barbosa, I E Souza,
I E Levi, R CM Succi (Brazil)
TuPeB4597 In vitro selection of the T215Y mutation by
stavudine (d4T) in viruses carrying 215D/C from
drug-naive persons
G Garcia-Lerma, H Maclnnes, S Nidtha, D Bennett,
H Weinstock, W Heneine (United States)
TuPeB4598 Performance of RECall basecalling software for
high-throughput HIV Drug resistance basecalling
using "in-house" methods
W Dong1, B Wynhoven', T Mo, T Hall, R A Galli,
PR Harrigan' (Canada; 2United States)
TuPeB4599 Resistance mutations in children infected with
Non-Subtype B HIV following HAART
D Auerbuck, M J Shapiro, D Engelhard, A Kedem,
G Gottesman, TZ Handzel, M Ofir, E Mendelson,
H Rudich, E Shahar, M Chowers, S Maayan,
Z Grossman (Israel)
TuPeB46oo The prevalence and determinants of the K65R
mutation in HIV reverse transcriptase in tenofovir
naive patients
A Winston S Mandalia, D Pillay, B Gazzard,
A Pozniak (United Kingdom)
TuPeB46ol Baseline genotypic patterns in antiretroviralnaive chronically HIV-infected patients included
in a prospective, multicenter, open-label,
randomized, antiretroviral therapy trial in Spain
(AMADEUS-ol Trial)
A Antela, JA Iribarren, V de Miguel, I Santos,
E Ribera, P Labarga, I Gonzdlez, I Locutura,
A Mufloz, A Andfa, L Moreno, M E Moreno,
C Gutidrrez, Y Mart[n, P Martf-Belda (Spain)
TuPeB46o2 Use of nucleoside analogues and development of
resistance in subtype B and subtype C infected
patients
Z Grossman, N Vardinon, M Burke, M Lorber,

I Levi, K Risenberg, M Chowers, V Istomin, D Ben
David, D Averbuck, D Ram, F Mileguir, Z Bentwich,
S Pollack, I Yust, S Maayan, I M Schapiro (Israel)

100 Final Program